Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
series C
Biotech
J&J-backed Delix secures $100M for non-hallucinatory psychedelic
Delix raised $100 million in a series C round backed by the likes of J&J to advance a phase 2-ready non-hallucinatory psychedelic for depression.
Marissa Russo
Nov 9, 2026 10:30am
OMass’ $310M raise fuels goal to become ‘Britain’s Big Biotech’
Oct 15, 2026 2:00am
Sling reels in $123M to fund oral Tepezza rival through ph. 3
Sep 16, 2026 7:00am
AusperBio adds $120M series C to push hep B drug through ph. 3
Aug 28, 2026 10:26am
Terremoto takes $108M series C to fuel trials of AKT1 inhibitors
Apr 15, 2026 7:43am
Endogenex nets $50M to develop pulsed-field diabetes procedure
Mar 25, 2026 10:48am